Comparison tool

Compare two products.
See the context clearly.

Review product identity, available documentation, study context and open questions side by side.

Suggested comparisons

Start with a useful comparison.

These examples show different products and research contexts. They are not rankings or recommendations.

Choose two products

What would you like to compare?

Product AProduct B

Peptide · Vial

BPC 157

BPC 157 is a synthetic 15-amino-acid peptide. Most published research is made up of cell, tissue and animal experiments rather than adequately controlled human trials.

View product

Evidence statusPreclinical evidence; human efficacy not established

Product details

Format: Vial
Labelled strength: 10mg
Batch record: BPC 004-012
Reported result: 99.2%

Questions in the literature

Tendon and connective-tissue modelsAnimal and laboratory models

Wound-response pathwaysHypothesis-generating evidence

Human outcomesMajor evidence gap

Study context

Transected Achilles tendon in rats with in-vitro tendocyte experiments

Investigators reported improved tendon measures and changes in tendocyte growth under the study conditions.

A rat injury model cannot establish clinical benefit, dose, route or safety in humans.

FDA review of BPC-157-related bulk substances

FDA identified limited safety information plus potential immunogenicity and peptide-impurity concerns.

A purity percentage does not resolve route-specific safety, immunogenicity or human-efficacy gaps.

What remains unknown

No established therapeutic indication or adequately characterized benefit-risk profile for human use.
Human pharmacokinetics, route-specific safety and long-term adverse effects remain insufficiently characterized.
Findings from one experimental formulation cannot authenticate or predict the performance of a separately sourced material.

Peptide · Vial

TB 500

TB-500 commonly refers to the LKKTETQ fragment associated with thymosin beta 4. Full-length thymosin beta 4 is a 43-amino-acid peptide; the fragment and parent peptide must not be treated as the same molecular entity.

View product

Evidence statusFragment-specific human evidence absent; full-length thymosin beta 4 evidence is not interchangeable

Product details

Format: Vial
Labelled strength: 10mg
Batch record: TB5 004-016
Reported result: 99.3%

Questions in the literature

Actin and cell migrationMechanistic evidence

Topical ophthalmic researchFormulation-specific human trial

TB-500 fragmentDirect human evidence gap

Study context

Randomized, double-masked phase 2 study of topical full-length thymosin beta 4

The two primary endpoints were not significantly different; selected secondary outcomes were reported.

A topical full-length peptide study is not evidence for an injectable fragment.

FDA review of thymosin beta 4 fragment (LKKTETQ/TB-500)

FDA reported no identified human exposure data and insufficient information to characterize harm.

Evidence for the parent peptide cannot fill a fragment-specific safety gap.

What remains unknown

Human pharmacology and safety of the TB-500 fragment are not established.
Product naming can obscure whether the tested material is full-length thymosin beta 4 or a fragment.
Route, formulation and purity data cannot substitute for molecularly matched clinical evidence.

How to use this comparison

Compare identity, documentation and the maturity of the published evidence. This view does not rank products, establish equivalence, recommend use or convert study findings into product-performance claims.